



**Current as of October 13, 2025**

## **Late-Breaking/Clinical Trial Abstracts to be presented**

### **Poster Session A (To be presented October 23, 2025, 12:30-4pm ET)**

**LB-A001 Biparatopic TNFR2 antagonist reverses immunosuppression and elicits robust anti-tumor responses without crosslinking agonism and ADCC dependence.** Zhichao(Eric) Ai. China Innovation Center of Roche (CICoR), Shanghai, China.

**LB-A003 A phase 1 trial of LY4175408, an antibody drug conjugate targeting protein tyrosine kinase 7-expressing tumor cells, in patients with advanced solid tumors (Trial in Progress).** Alexander Spira. NEXT Oncology Virginia, Fairfax, VA, United States.

**LB-A004 A phase 1, first in human, open-label multicenter study to evaluate ALX2004, antibody–drug conjugate targeting EGFR, in patients with advanced or metastatic select solid tumors (ALX2004-01).** Alexander Spira. Virginia Cancer Specialists, Fairfax, VA, United States.

**LB-A005 A dependency map of acquired vulnerabilities in cancer drug resistance.** Florencia Madorsky Rowdo. Broad Institute, Cambridge, MA, United States.

**LB-A006 A Phase 1/2 Study of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC).** Somi Lee. Voronoi, Inc., Incheon, United States.

**LB-A007 CAR-T cell therapy targeting MUC17 for gastric cancer treatment.** Cassidy Ho. Massachusetts General Hospital, Boston, MA, United States.

**LB-A008 Bugs delivering drugs: Listeria monocytogenes-mediated cytotoxin delivery produces anti-tumor activity in colorectal cancer.** Wyatt Paulishak. Baylor University, Waco, TX, United States.

**LB-A009 Results from Part 1 of ON-5001: a multi-center, dose escalation and dose finding Phase 1 trial of ONM-501, a dual-acting STING agonist, alone or in combination with cemiplimab in patients with solid tumors and lymphoma.** Joal Beane. The Ohio State University, Columbus, OH, United States.

**LB-A010 Single-cell transcriptomic profiling and machine learning-driven QSAR modeling for target drug discovery in lung cancer.** Nagasundaram Nagarajan. University of Nebraska Medical Center, Omaha, NE, United States.

**LB-A011 Preliminary results from a phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor  $\alpha$ -targeting antibody-drug conjugate, in patients with**



**advanced solid tumors.** Patricia LoRusso. Yale Cancer Center, New Haven, CT, United States.

**LB-A012 Development and Validation of a Model for Individual Prediction of Recurrence in Patients with AJCC Stage IIIA Melanoma.** Andrea Maurichi. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

**LB-A013 Novel covalent WRN inhibitors SHC0646151 and SHC0646198 for the treatment of microsatellite instability-high (MSI-H) cancers.** Cheng Ge. Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing, China.

**LB-A014 Dual PI3K and RAS pathway inhibition overcomes therapeutic resistance in KRAS/PIK3CA co-mutant colorectal cancer patient-derived organoids.** Alice Shin. Division of Digestive and Liver Diseases, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons; Columbia University Irving Medical Center, New York, NY, United States.

**LB-A015 A phase I/IIa study to evaluate the safety and tolerability, activity and PK of a potential novel CNTN4-targeted checkpoint inhibitor, EP0089, in patients with advanced solid tumors.** Hendrik-Tobias Arkenau. Ellipses Pharma, London, United Kingdom.

**LB-A016 Regulating m6A-RNA modification as new therapies for cancer.** Tariq Rana. UC San Diego, La Jolla, CA, United States.

**LB-A017 A Phase 1, First-in-Human, Dose-Escalation Study of VRN101099, a Brain-Penetrant HER2 TKI, in Patients with Advanced HER2 Alteration Solid Tumors.** Hong-ryul Jung. Voronoi, Inc., Incheon, United States.

**LB-A018 Phase 1 study of PHST001, a humanized anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.** Kyri Papadopoulos. South Texas Accelerated Research Therapeutics (START), San Antonio, TX, United States.

**LB-A019 Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900.** Gerald Falchook. Sarah Cannon Research Institute at HealthOne, Denver, CO, United States.

**LB-A020 Targeting of FOXA1 and FOXA2 by small molecule inhibitors disrupts the lineage-specific oncogenic output program in prostate cancer.** Jean-Philippe Theurillat. Institute of Oncology Research, Bellinzona, Switzerland.

**LB-A021 Zanidatamab in patients with advanced HER2-positive salivary gland cancer: A pooled analysis of early-phase studies.** Funda Meric-Bernstam. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.



**LB-A022 Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers.**

Joshua Lange. Boundless Bio, San Diego, CA, United States.

**LB-A023 WDR62 role as a predictive biomarker of Oxaliplatin–Emetine chemotherapeutic synergy in KRASG12D mutated pancreatic ductal adenocarcinoma .**

SDANISH KADIR. University of Texas Rio Grande Valley, Edinburg, TX, United States.



## **Poster Session B (To be presented October 24, 2025, 12:30-4pm ET)**

**LB-B001 Therapeutic Targeting of FXR1 Expressing Tumors Using LNA form of siRNA.** Pradeep Chaluvally-Raghavan. Medical College of Wisconsin, Milwaukee, WI, United States.

**LB-B002 Anti-OSMR antibodies inhibit tumor growth and metastasis of ovarian cancer.** Pradeep Chaluvally-Raghavan. Medical College of Wisconsin, Milwaukee, WI, United States.

**LB-B003 Phase 1 trial of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer.** Grace K. Dy. Roswell Park Comprehensive Cancer Center, Buffalo, United States.

**LB-B004 Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNACLE Phase 2 trial.** Alison Schram. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

**LB-B005 A phase I trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).** Glenn Hanna. Dana Farber Cancer Institute, Boston, MA, United States.

**LB-B006 Preliminary safety, pharmacokinetics, and antitumor activity of HLD-0915, a first-in-class oral RIPTAC™ binding androgen receptor (AR) and bromodomain 4 (BRD4), in patients with metastatic castrate resistant prostate cancer (mCRPC).** Andrew Hahn. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

**LB-B007 Safety and clinical activity of FX-909, a first-in-class oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), a master regulator of luminal lineage in patients with advanced urothelial carcinoma.** Xin Gao. Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

**LB-B008 A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRAS G12D mutation.** Ignacio Garrido-Laguna. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.

**LB-B009 Preliminary findings from the first-in-human SOLARA trial of BH-30643, a novel macrocyclic, non-covalent, mutant selective, brain active, OMNI-EGFR inhibitor, in EGFR-mutant NSCLC.** Alexander Spira. NEXT Oncology, Fairfax, VA, United States.

**LB-B010 Efficacy and safety of ASP3082, a novel protein degrader, as monotherapy in patients (pts) with non-small cell lung cancer (NSCLC) with KRAS G12D mutation.** Alexander Spira. Virginia Cancer Specialists and NEXT Oncology-Virginia, Fairfax, VA, United States.

**LB-B011 Sevabertinib (BAY 2927088), a reversible HER2 inhibitor with activity in lung cancer.** Heidi Greulich. Broad Institute, Cambridge, MA, United States.



**LB-B012 Integrating Machine Learning and High Throughput Screening to Identify Chemical Probe Candidates Targeting Aldehyde Dehydrogenases.** Adam Yasgar. National Center for Advancing Translational Sciences (NCATS), Rockville, MD, United States.

**LB-B013 A phase 1b, multicenter, open-label dose-escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer.** Jeroen Dekervel. University Hospital Gasthuisberg and University of Leuven (KULeuven), Leuven, Belgium.

**LB-B014 A phase 1/2 study of AVZO-1418, a bispecific antibody-drug conjugate (ADC), as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumors.** Anthony Tolcher. NEXT Oncology, San Antonio, TX, United States.

**LB-B015 CEACAM5 pre-targeting via click chemistry enables tumor-selective MMAE activation: A first-in-class approach to enhance clinical benefit in targeted therapy.** Masa Aleckovic. Shasqi Inc, San Francisco, CA, United States.

**LB-B016 Development of hypoxia-activated prodrugs of AMPK inhibitors and evaluation in acute myeloid leukemia.** Caleb Chandler. University of Colorado - Anschutz, Aurora, CO, United States.

**LB-B017 O-mannosylation and protein maturation checkpoints represent therapeutic opportunities in BRAF fusion protein oncogenesis.** Anna Borgenvik. Dana-Farber/ Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States.

**LB-B018 In situ detection of WRN activity and R-loops accumulation at DNA double-strand breaks using the STRIDE platform.** Zsombor Prucsi. intoDNA, Krakow, Poland.

**LB-B019 RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in patients with previously treated RAS-mutant NSCLC.** Ferdinandos Skoulidis. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

**LB-B020 A CRISPR/Cas9 pipeline in patient-derived xenograft models in vivo identifies attractive therapeutic targets.** Irmela Jeremias. Helmholtz Center Munich, German Research Center for Environmental Health (HMGU), Munich, Germany.

**LB-B021 Open label, multicenter, phase 2 study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib in platinum-resistant ovarian cancer (PROC).** Robert Wenham. Moffitt Cancer Center, Tampa, FL, United States.

**LB-B022 Safety of 4 mg/kg and 5 mg/kg doses of sacituzumab tirumotecan (sac-TMT) in unresectable locally advanced/metastatic solid tumors: 2870-001/KL264-01 study.** Jordi Rodon. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States.



**LB-B023 Creating a resource for the discovery of isoforms and fusion events in cancer cell lines..** Kirsty Wienand. Broad Institute of MIT and Harvard, Cambridge, MA, United States.

**LB-B024 Efficacy and safety of Elironrasib, a RAS(ON) G12C-selective inhibitor, in patients with KRAS G12C NSCLC following treatment with a KRAS(OFF) G12C inhibitor.** Bruna Pellini. Moffitt Cancer Center and Research Institute, Tampa, United States.



## **Poster Session C (To be presented October 25, 2025, 12:30-4pm ET)**

**LB-C001 Discovery of AN4035: A Novel CEACAM5-Targeting Antibody Drug Conjugate (ADC) Armed with a Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window.** Archie Tse. Adlai Nortye Ltd., Hangzhou, China.

**LB-C002 Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification.** Benjamin Herzberg. Columbia University, New York, NY, United States.

**LB-C003 Discovery and characterization of a highly potent and orally available SMARCA2 PROTAC degrader.** Haiyan Ying. Abbisko Therapeutics, Shanghai, China.

**LB-C004 Transposon-Based BAFF CAR-T cells (LMY-920) for Treatment of Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Lymphoma (CLL) and Multiple Myeloma (MM).** Paolo Caimi. Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH, United States.

**LB-C005 Bombesin-conjugated ICG nanobubbles for multimodal imaging of prostate cancer aggressiveness.** Bhawna Saini. Pennsylvania State University, Hershey, PA, United States.

**LB-C006 Mapping mitotic stress vulnerabilities: Genome-wide identification of genes safeguarding ultrafine anaphase bridges under topoisomerase II inhibition .** Christina Andronikou. Roche Innovation Center Basel, Roche Pharma Research and Early Development (pRED), Basel, Switzerland, Basel, Switzerland.

**LB-C007 FMC-242, a highly potent and selective covalent inhibitor of the PI3Ka-RAS interaction that demonstrates improved efficacy and tolerability as monotherapy and in combination with targeted therapies in preclinical models.** Kevin Webster. Frontier Medicines, Boston, MA, United States.

**LB-C008 Safety and patient-reported outcomes with tepotinib in patients with METex14 skipping NSCLC: ≥3-years follow-up of VISION.** Paul Paik. Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

**LB-C009 Treatment (Tx) sequencing of tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study.** Paul Paik. Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

**LB-C010 Tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes.** Paul Paik. Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.



**LB-C011 Modeling TNBC intertumor heterogeneity using a novel 3D culture platform.**

Xiaoqing Xu. Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School and Boston Children's Hospital, Boston, MA, United States.

**LB-C012 Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody .** Yuki Majima. Toray Industries, Inc., Kamakura, Japan.

**LB-C013 WSB1-Mediated Degradation of PSMA Drives Neuroendocrine Differentiation in Early Prostate Cancer.** Dawa Jung. Mayo Clinic, Rochester, MN, United States.

**LB-C014 Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies.** Ananya Banerjee. University of Michigan, Ann Arbor, MI, United States.

**LB-C015 Neoadjuvant PD-1 blockade combined with therapeutic DNA vaccine and IL-7 reshapes intratumoral immunity in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC).** Hye Ryun Kim. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, United States.

**LB-C016 BEGIN: A Basket Trial of Glutaminase inhibition with Telaglenastat in NF1, KEAP1/NRF2, and STK11/LKB1-Altered Tumors.** Mohamed Gouda. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

**LB-C017 A Massively Parallel - Mixed Lymphocytes Reaction to Reveal Donor Heterogeneity in Pooled Screening of CAR-T Cells.** Lujing Wu. Stanford University, Palo Alto, CA, United States.

**LB-C018 Defining Clinical and Molecular Determinants of Treatment Benefit and Survival in Early Phase Immunotherapy Trials.** Harold Nathan Tan. MD Anderson Cancer Center, Houston, TX, United States.

**LB-C019 CTC-RACE: A microfluidic single-cell motility assay reveals functional heterogeneity of circulating tumor cells in lung, head and neck, and triple-negative breast cancer.** Yang Liu. University of Georgia, Athens, GA, United States.

**LB-C020 Preclinical and Clinical Activity of VRN101099, a Novel Covalent HER2 TKI for Metastatic HER2-Driven Solid Tumors.** Hong-ryul Jung. Voronoi, Inc., Incheon, United States.

**LB-C021 Topoisomerase 1 and DNA damage pharmacodynamic responses and proof of mechanism of trastuzumab deruxtecan in HER2- expressing advanced solid tumors.** Deborah Wilsker. Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.



**LB-C022 A chemical probe designed to capture MET reveals Aurora kinase A but not MET expression as the primary target for sensitizing cells to paclitaxel.** Malak Selim. McGill University, Montreal, QC, Canada.

**LB-C023 Development of tumor-on-a-chip and PDX derived cell culture models of glioblastoma (GBM) for assessment of drug sensitivity and permeability .** Lars Winkler. Experimental Pharmacology and Oncology GmbH, Berlin, Germany.

**LB-C024 Secretome of Primed MSCs in Defined Serum-Free Media Exhibits Pro-Myelinating Potential Against Progressive CNS Demyelination.** Kshama Gupta. Cornell University, New York, NY, United States.

**LB-C025 EP102: Pharmacological Inhibition of METTL3 arrests tumor growth in NSCLC adenocarcinoma; comparative data versus an EGFR inhibitor..** Graeme Fraser. EPICS Therapeutics, Gosselies, Belgium.

**LB-C026 Understanding FANCM's function in the telomeres of ALT cancer cells.** Silvia Sberna. Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.